Dirk Weber

Institution: Cellestia Biotech AG, Basel


Hochbergerstrasse 60C 4057 Basel

Email: dirk.weber@cellestiabiotech.com

Group website: www.cellestiabiotech.com

Phone: 079 9441580

Research interests:

Cellestia Biotech AG is a privately owned biopharmaceutical company located in Basel and Lausanne, Switzerland, with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway. The lead product CB-103 is a novel, first-in-class, oral pan-NOTCH inhibitor for treatment of NOTCH dependent leukemia, lymphoma and solid tumor indications including also breast cancer as a very important indication. Activation of the NOTCH pathway in breast cancer has shown to have a negative prognostic effect of the patients leading to a shorter survival. In particular TNBC is a very promising indication for treatment with our lead product CB-103 as there is a group of TNBC patients with constitutive activation of the NOTCH pathway (chromosomal translocation)which maybe responsive to CB-103 treatment in a unique fashion based on the very distinct mode of action of CB-103 by binding to the nuclear transcription complex of NOTCH. Cellestia is currently preparing for a FIH phase I/IIA study with CB-103 with a focus on recruiting breast cancer patients in particular with patient enrichment based on NOTCH pathway activation planned to be included in phase IIA of this study. I am representing the company as CMO and be responsible for the clinical development of CB-103. I have worked n the past in late stage development of products for breast cancer and have strong interest in developing CB-103 in patients with NOTCH-positive breast cancer.

Selected publications:

Hoffend, J., Mier, W., Nollert, J., Eisenhut, M., Bosch, F.X., Dietz, A., Weber, D., Tillner, J., Henschel, V., Haberkorn, U. (2005) Tumor Uptake of Iodine-123-EMD 72000 (Matuzumab), a Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Submitted to Journal of Nuclear Medicine Graeven, U., Kremer, B., Südhoff, T., Killing, B., Rojo, F., Weber, D., Tillner, J., Schmiegel, W. (2006) A phase I study of the humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in patients with advanced pancreatic cancer. BRITISH J. OF CANCER 94, 1293-1299, 2006 M.V. Seiden, H.A. Burris, U. Matulonis, J.B. Hall, D. Armstrong, J. Speyer D. Weber, F. Muggia (2007) A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. GYNECOLOGIC ONCOLOGY, Volume 104, Issue 3, Pages 727–731, March 2007 C. Oehler, K. Frei, E. J. Rushing, P. M. J. McSheehy, D. Weber, P. R. Allegrini, D. Weniger, U. Lütolf, A. Knuth, Y. Yonekawa, K. Barat, A Broggini-Tenzer, M. Pruschy, S. Hofer (2012) Patupilone (Epothilone B) for recurrent Glioblastoma: clinical outcome and translational analysis of a single institution Phase I/II trial ONCOLOGY, Volume 8, Pages 1–9, June 2012 K. N. Chi, E. Beardsley, B. J. Eigl, P. Venner, S. J. Hotte, E. Winquist, Y.-J. Ko, S. S. Sridhar, D. Weber, F. Saad (2012) A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a ANNALS OF ONCOLOGY, Volume 23: pages 53–58, 2012 W. M. Smit, J. Sufliarsky, T. L. Werner, D. Dizon, M. Wagnerova, H. W. Hirte, N. Spirtos, A. Oza, L. Dirix, M. El-Hashimy, S. Acharyya, E. Y. Tan, D. Weber, J. H. M. Schellens (2012) A Phase II Study of Patupilone (EPO906) in Patients with Platinum-Resistant or –Refractory Ovarian Canceccepted for publication in Clinical Ovarian Cancer and Other Gynecologic Cancer. Accepted by CLIN OVARIAN CANCER AND OTHER GYNECOLOGIC CANCER 2012 N. Colombo, E. Kutarska, M. Dimopoulos, D-S. Bae, I. Rzepka-Gorska, M. Bidzinski, G. Scambia, S. A. Engelholm, F. Joly, D. Weber, M. El-Hashimy, J. Li, E. Tan, F. Souami, P. Wing, S. Engelholm, A. Bamias, P. Schwartz (2012) A Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) to Pegylated Liposomal Doxorubicin in Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer JOURNAL OF CLINICAL ONCOLOGY 2012; published online on 17Sep12 ahead of printing

Members List